The financing allows Lumen Bioscience to continue developing technology that uses the algae spirulina to make biologics.
Seattle biotech startup Lumen Bioscience raises $11.2M to develop drugs using algae
Recent Post
Cognition Live Article on RePreve Trial
LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial
Preventive antimicrobials: A promising solution to antibiotic resistance
Preventive Biologics May Aid the Antibiotic Resistance Crisis
Q&A: Biologic drugs are reinvented to treat infectious diseases